ELPIS SELTERAPYUTICS

About ELPIS SELTERAPYUTICS

Elpis Biopharmaceuticals is a clinical-stage biopharmaceutical company established in 2017 by Founder and CEO Dr. Yan Chen and Co-founder Dr. Kehao Zhao. The company focuses on developing immunotherapies to treat difficult-to-treat and resistant cancers.

Dr. Chen has over two decades of experience in mRNA display technology and biologic drug discovery in oncology, having held positions at Juno Therapeutics and Novartis Institutes for Biomedical Research. Her work at companies like Phylos and Adnexus was instrumental in establishing mRNA antibody and protein display technology platforms. This extensive background in antibody engineering and immuno-oncology directly led to the founding of Elpis to address cancer resistance with multifunctional therapeutics. Dr. Zhao brings more than 15 years of drug discovery experience from his time at Novartis and Procter & Gamble Pharmaceuticals.

Elpis operates with a business model centered on the discovery and development of its proprietary therapeutic pipeline, financed through venture capital and strategic partnerships. In October 2020, the company secured a $30 million Series A financing, bringing its total raised funds to $40 million. The company has headquarters in Lexington, Massachusetts, and Singapore.

The company's core technology includes several proprietary platforms. The mADs™ platform is for discovering fully human therapeutic antibodies, while the mSCAFold™ platform develops novel protein therapeutics. More recently, the company has highlighted its integrated platforms which include a multi-mechanism armor technology, bispecific targeting antibodies, and a rapid mRNA display discovery engine to create safer and more effective treatments. These platforms are designed to overcome key challenges in cancer therapy, such as tumor heterogeneity and the immunosuppressive tumor microenvironment (TME). Elpis is advancing a pipeline of bi-specific antibodies and dual-targeting CAR-T therapies. Lead programs include EPC-003 for glioblastoma and EPC-002 for a range of solid tumors. The company has also entered into research collaborations, such as one with Singapore General Hospital, to develop next-generation allogeneic CAR technologies.